Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone propionate
Drug ID BADD_D00947
Description Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Indications and Usage Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358].
Marketing Status approved
ATC Code R03BA05; R01AD08; D07AC17
DrugBank ID DB00588
KEGG ID D01708
MeSH ID D000068298
PubChem ID 444036
TTD Drug ID D0LC6K
NDC Product Code 81522-002; 22552-0043; 51927-0013; 0113-0028; 41163-023; 0135-0582; 55910-607; 63868-656; 69842-765; 70000-0110; 72559-002; 46439-8729; 51552-1310; 11822-0901; 0113-0285; 37808-340; 41520-553; 0173-0601; 0173-0720; 50594-319; 53002-1294; 53002-7691; 59310-505; 59310-515; 0363-0652; 63629-8662; 63629-8663; 66993-078; 68788-7788; 0054-3270; 0713-0631; 80267-000; 81522-005; 16812-005; 64918-1600; 11673-262; 0173-0602; 0173-0718; 49035-063; 50090-0934; 53943-006; 55910-773; 60505-6205; 0363-0881; 63629-8658; 63629-8659; 64525-8000; 66993-079; 68196-208; 68788-8446; 68788-9678; 68998-600; 72189-004; 63654-380; 63981-001; 68196-210; 69842-757; 71143-375; 81522-073; 38779-2760; 53873-078; 55018-301; 11673-388; 46122-684; 49035-362; 50090-6053; 53002-1310; 53002-7693; 55301-506; 59310-114; 59310-311; 60505-0829; 63187-638; 63187-959; 63868-400; 64024-007; 68788-6926; 69306-016; 69842-900; 0536-1373; 49076-5501; 52482-001; 64918-1700; 11673-103; 11822-1177; 30142-258; 30142-301; 0113-7117; 36800-222; 0363-0024; 64525-6560; 69168-380; 70000-0613; 79903-071; 52221-106; 36800-572; 41163-100; 41250-634; 45802-222; 50090-2880; 50383-968; 59310-525; 62011-0269; 0363-1205; 63187-957; 68071-2582; 68071-4868; 68462-427; 0536-1183; 71205-443; 72288-119; 80425-0263; 53873-079; 63190-0520; 64918-1118; 37835-997; 0173-0719; 49348-182; 50090-0916; 50090-6058; 53002-2294; 60432-264; 63187-021; 63187-806; 0363-5012; 63629-8660; 63629-8661; 66993-080; 68016-723; 69842-770; 70518-1655; 0713-0632; 15308-0200; 58175-0361; 21130-089; 37808-205; 45802-221; 50090-6055; 50383-700; 56062-107; 59310-200; 60505-0955; 68391-133; 69256-061; 69842-228; 72288-333; 76162-656; 76420-106; 80159-201; 50909-5175; 63379-001; 11673-220; 21130-122; 36800-128; 41520-703; 46122-386; 51672-4095; 67296-1463; 53104-7531; 65089-0033; 0135-0576; 0168-0332; 0173-0600; 45802-441; 49035-200; 50090-0968; 51316-074; 60429-195
UNII O2GMZ0LF5W
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C25H31F3O5S
CAS Registry Number 80474-14-2
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast cancer16.10.01.001; 21.05.01.003--Not Available
Bronchial obstruction22.03.01.013--
Bronchiectasis22.03.02.005--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.0120.000590%
Bronchospasm paradoxical22.03.01.006--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.001659%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000184%Not Available
Carpal tunnel syndrome17.09.02.0010.000184%Not Available
Cataract06.06.01.0010.000682%
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000903%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.0030.002341%Not Available
Choking22.12.03.0030.000276%Not Available
Choking sensation22.12.03.004; 19.01.02.002--Not Available
Chromaturia20.02.01.002--
Chronic obstructive pulmonary disease22.03.01.0070.000645%Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Condition aggravated08.01.03.0040.001991%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.0010.005234%
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.000369%Not Available
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.0010.000922%Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.0020.000184%
Decreased activity19.11.01.002; 08.01.01.006--Not Available
Delirium19.13.02.0010.000184%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages